Literature DB >> 1271889

MER and other mycobacterial fractions in the immunotherapy of cancer.

D W Weiss.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271889     DOI: 10.1016/s0025-7125(16)31893-4

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


× No keyword cloud information.
  7 in total

Review 1.  Intralesional treatment for advanced melanoma: what's on the horizon?

Authors:  Sanjiv Agarwala
Journal:  Melanoma Manag       Date:  2016-05-25

2.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

3.  Immunotherapy of leukaemias: present status and future prospects.

Authors:  H D Flad
Journal:  Blut       Date:  1978-11-13

4.  Induction of controlled prostatic tissue necrosis by bacille Calmette-Guérin derivatives.

Authors:  A Morales; J C Nickel; P N Manley
Journal:  Urol Res       Date:  1991

5.  Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients.

Authors:  W C Wood
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Potentiation of mouse peritoneal macrophage antibacterial functions by treatment of the donor animals with the methanol extraction residue fraction of tubercle bacilli.

Authors:  R Gallily; Z Douchan; D W Weiss
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

Review 7.  Intralesional therapy for advanced melanoma: promise and limitation.

Authors:  Sanjiv S Agarwala
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.